Faron Pharmaceuticals Oy (LON:FARN - Get Free Report)'s share price crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of GBX 181.67 ($2.35) and traded as high as GBX 183 ($2.37). Faron Pharmaceuticals Oy shares last traded at GBX 173 ($2.24), with a volume of 122,619 shares changing hands.
Faron Pharmaceuticals Oy Stock Down 2.6 %
The business has a fifty day moving average of GBX 182.03 and a 200 day moving average of GBX 186.27. The company has a market capitalization of £224.20 million, a PE ratio of -4.47 and a beta of 0.36. The company has a current ratio of 1.45, a quick ratio of 1.09 and a debt-to-equity ratio of 922.55.
About Faron Pharmaceuticals Oy
(
Get Free Report)
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
See Also
Before you consider Faron Pharmaceuticals Oy, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Faron Pharmaceuticals Oy wasn't on the list.
While Faron Pharmaceuticals Oy currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
